Compare prices and buy Ipamorelin from 42 research peptide vendors - also called suppliers or sources. Updated daily.
A synthetic pentapeptide growth-hormone secretagogue with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 (CAS 170851-70-4), developed by Novo Nordisk under code NNC 26-0161. Agonizes the ghrelin/GHS-R1a receptor to trigger pulsatile GH release, without the rise in ACTH and cortisol that GHRP-2 and GHRP-6 produced in the swine study that introduced it, the finding behind its description as the first selective growth hormone secretagogue. Its only registered human trials, in postoperative ileus, went no further than Phase 2, and it holds no FDA approval.
For research purposes only. Not medical advice.
Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, molecular formula C38H49N9O5. It was developed at Novo Nordisk under the code NNC 26-0161 and described by Raun and colleagues in the European Journal of Endocrinology in 1998. It emerged from a chemistry programme built around growth hormone-releasing peptide-1, and its defining structural move was dropping the central Ala-Trp dipeptide the earlier GHRPs carried.
Three of its five residues are not standard amino acids: 2-aminoisobutyric acid at the N-terminus, D-2-naphthylalanine, and D-phenylalanine. Substitutions of that kind are a standard way to resist the proteases that clear a natural sequence, and they are also the feature the FDA names when it describes ipamorelin as complex to characterize.
Ipamorelin agonizes the ghrelin receptor, GHS-R1a, on pituitary somatotrophs, prompting the gland to release its own growth hormone in pulses. Sermorelin, tesamorelin and CJC-1295 reach a similar output through a different receptor, the GHRH receptor. GHRP-2, GHRP-6 and hexarelin act at the same one ipamorelin does. Tesamorelin vs sermorelin vs ipamorelin compares ipamorelin with the two GHRH analogs across receptors, trials and regulatory history.
The 1998 paper's claim to novelty was selectivity. Ipamorelin released growth hormone in rats and swine with potency and efficacy comparable to GHRP-6, but where GHRP-6 and GHRP-2 both raised plasma ACTH and cortisol, ipamorelin did not, at doses more than 200-fold above its ED50 for GH release. That result is the origin of the "first selective growth hormone secretagogue" description that follows the compound around. None of the secretagogues in that study moved FSH, LH, prolactin or TSH, so the distinguishing finding concerned ACTH and cortisol alone.
Ipamorelin's registered human trials are two Phase 2 studies, both sponsored by Helsinn Therapeutics and both in postoperative ileus rather than growth hormone deficiency. NCT00672074, a double-blind placebo-controlled study in 117 patients, ran from 2008 to 2009. NCT01280344, a dose-finding study of 320 patients recovering from small or large bowel resection with primary anastomosis, ran from 2011 to 2014. Both are recorded as completed, but neither has results posted on ClinicalTrials.gov. NCT00672074 was published in 2014, and Beck and colleagues reported no significant difference between ipamorelin and placebo in its key or secondary efficacy analyses. No Phase 3 followed. Ipamorelin holds no FDA approval.
On September 29, 2023, the FDA placed ipamorelin acetate in Category 2 under both its 503A and 503B interim bulk drug substances policies, the category for substances the agency considers to raise significant safety risks. Its stated concerns were immunogenicity from aggregation and peptide-related impurities, the characterization difficulty introduced by those unnatural residues, and a published report of serious adverse events including death when ipamorelin was given intravenously to improve gastric motility.
In September 2024, the agency removed ipamorelin acetate from Category 2 under the 503A policy because its nominators withdrew the nominations. The same FDA update noted that the agency would still consult the Pharmacy Compounding Advisory Committee on ipamorelin-related substances on October 29, 2024, and the review went ahead without a nominator presentation. The committee voted 12 to 1 to take the two forms as a group, but under FDA's rule a single dissent sent each to its own poll, and it rejected both by identical margins: no votes in favor, twelve against, one abstention. FDA had recommended against inclusion. Ibutamoren mesylate and kisspeptin-10 were also voted down that day.
Selank left 503A Category 2 in the same September 2024 update, for a different reason. Ipamorelin was heard and voted down, and ipamorelin acetate remains listed in Category 2 under the separate 503B interim policy. It was not among the twelve peptides removed in April 2026, because it had already left 503A Category 2 nineteen months earlier.
Listings are usually plain "Ipamorelin" or the shorthand "Ipamo," and rarely state whether the material is the free base or the acetate salt, two forms FDA treats as different bulk drug substances. The compound is also sold blended with a GHRH analog, a pairing that is a market convention rather than a pharmacological one.
PeptideScouter indexes ipamorelin vials per milligram and verifies identity against its molecular formula rather than the product title.
Yes. The Pharmacy Compounding Advisory Committee heard ipamorelin-related bulk drug substances on October 29, 2024, for the uses FDA evaluated: growth hormone deficiency and postoperative ileus. The committee voted 12 to 1 to consider ipamorelin (free base) and ipamorelin acetate together, and because FDA's rule required separate polls if any member dissented, it then rejected each by identical margins, with no votes in favor, twelve against and one abstention each. FDA had recommended against including either on the 503A bulks list.
Because it had already come out nineteen months earlier. FDA placed ipamorelin acetate in Category 2 on September 29, 2023, and removed it from Category 2 under the 503A interim policy in September 2024, after its nominators withdrew the nominations. The April 2026 action covered a different set of twelve peptides. Ipamorelin acetate is still listed in Category 2 under the separate 503B interim policy.
They are the same peptide in different forms, the free base and its acetate salt, and vendor listings rarely say which one they are selling. The distinction is not purely academic: FDA evaluated the two separately, and the advisory committee took two separate votes. Because a salt form carries additional mass, a milligram figure on a label refers to whichever form the material actually is, so a certificate of analysis is the only way to know which was supplied.
The receptor. Ipamorelin acts at the ghrelin receptor, GHS-R1a, the same target as GHRP-2, GHRP-6 and hexarelin. CJC-1295, sermorelin and tesamorelin are GHRH analogs and act at the GHRH receptor instead. Both routes end at the pituitary releasing its own growth hormone, but they are mechanistically distinct pathways rather than variations on one compound.
Postoperative ileus, not growth hormone deficiency. Helsinn Therapeutics sponsored two Phase 2 trials: a double-blind placebo-controlled study in 117 patients that ran from 2008 to 2009, and a dose-finding study in 320 patients recovering from small or large bowel resection with primary anastomosis that ran from 2011 to 2014. Both are recorded as completed, neither has posted results on ClinicalTrials.gov, and no Phase 3 program followed. The first trial was published in 2014 and reported no significant difference from placebo in its key or secondary efficacy analyses. Ipamorelin holds no FDA approval.
Ipamorelin is sold by 42 research peptide vendors indexed on PeptideScouter, with 68 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
All 42 indexed research peptide vendors currently have Ipamorelin in stock. Stock state is refreshed daily from each vendor's catalog.
Studz Peptides currently lists Ipamorelin at $2.00/mg, the lowest listed price across 42 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $1.80/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 42 vendors listing Ipamorelin publish a PeptideScouter code, worth 5% to 50% off. Applied, the lowest effective price falls from $2.00/mg listed to $1.80/mg at Studz Peptides. Each vendor's code is shown beside its price in the table above.
Ipamorelin ranges from $2.00/mg to $10.00/mg across 68 listings from 42 research peptide vendors, normalized to USD per milligram and refreshed daily.
42 research peptide vendors currently list Ipamorelin on PeptideScouter. We track 68 listings across size and kit variants.
Ipamorelin's CAS Registry Number is 170851-70-4. It is also sold as Ipamo.
